Home Other Building Blocks Nimorazole

Nimorazole

CAS No.:
6506-37-2
Catalog Number:
AG00E931
Molecular Formula:
C9H14N4O3
Molecular Weight:
226.2325
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
99%(HPLC)
In Stock USA
United States
$60
- +
25mg
99%(HPLC)
In Stock USA
United States
$100
- +
100mg
99%(HPLC)
In Stock USA
United States
$186
- +
500mg
99%(HPLC)
In Stock USA
United States
$486
- +
Product Description
Catalog Number:
AG00E931
Chemical Name:
Nimorazole
CAS Number:
6506-37-2
Molecular Formula:
C9H14N4O3
Molecular Weight:
226.2325
MDL Number:
MFCD00866796
IUPAC Name:
4-[2-(5-nitroimidazol-1-yl)ethyl]morpholine
InChI:
InChI=1S/C9H14N4O3/c14-13(15)9-7-10-8-12(9)2-1-11-3-5-16-6-4-11/h7-8H,1-6H2
InChI Key:
MDJFHRLTPRPZLY-UHFFFAOYSA-N
SMILES:
[O-][N+](=O)c1cncn1CCN1CCOCC1
EC Number:
229-394-4
UNII:
469ULX0H4G
NSC Number:
107524
Properties
Complexity:
239  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
226.107g/mol
Formal Charge:
0
Heavy Atom Count:
16  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
226.236g/mol
Monoisotopic Mass:
226.107g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
76.1A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-0.4  
Literature
Title Journal
Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerging infectious diseases 20120601
Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20120101
Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy. Frontiers in pharmacology 20120101
Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials. Acta oncologica (Stockholm, Sweden) 20111001
[Development and use of test systems for the evaluation of sensitivity of Trichomonas vaginalisto preparations of the 5-nitroimidazole and 5-nitrofuran groups]. Zhurnal mikrobiologii, epidemiologii, i immunobiologii 20110101
HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20100101
Tinidazole in the treatment of bacterial vaginosis. International journal of women's health 20090101
Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20080601
The nimorazole regimen in patients with head and neck cancer can increase the effect of vitamin K antagonists. Acta oncologica (Stockholm, Sweden) 20080101
Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer. Current oncology (Toronto, Ont.) 20080101
[The Oxygen effect: an old new target?]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20080101
Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials. Breast cancer research : BCR 20080101
Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20071001
The importance of radiobiology to cancer therapy: current practice and future perspectives. Clinical oncology (Royal College of Radiologists (Great Britain)) 20070801
Chemical radiosensitizers for use in radiotherapy. Clinical oncology (Royal College of Radiologists (Great Britain)) 20070801
Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20070601
Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20070601
Motexafin gadolinium injection for the treatment of brain metastases in patients with non-small cell lung cancer. International journal of nanomedicine 20070301
Microsphere-based protease assays and screening application for lethal factor and factor Xa. Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells. Anticancer research 20060101
Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC cancer 20060101
Update on clinical radiobiology. Biomedical imaging and intervention journal 20060101
Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo. Journal of radiation research 20051201
Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. The Lancet. Oncology 20051001
Nimorazole may increase the effect of phenprocoumon. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20050301
Probing NMR parameters, structure and dynamics of 5-nitroimidazole derivatives. Density functional study of prototypical radiosensitizers. Magnetic resonance in chemistry : MRC 20050201
Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia. British journal of cancer 20040913
Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model. British journal of cancer 20040719
Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20040601
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet (London, England) 20030920
Nitroheterocyclic drugs with broad spectrum activity. Parasitology research 20030601
Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20030101
A systematic overview of radiation therapy effects in head and neck cancer. Acta oncologica (Stockholm, Sweden) 20030101
Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU. British journal of cancer 19820801
Properties